3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neurofibromatosis 1
12
Neurofibroma, Plexiform
6
Carcinoma, Non-Small-Cell Lung
4
Neurofibrosarcoma
3
Neoplasms
3
Lung Neoplasms
3
Melanoma
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Recurrence
1
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
Pain
1
Neoplasm Metastasis
1
Muscle Invasive Bladder Cancer
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Kidney Neoplasms
1
Gallbladder Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Astrocytoma
1
Advanced Non Small Cell Lung Cancer
1
Adenocarcinoma
1
Interventions
pembrolizumab
105
Specimen Handling
55
Magnetic Resonance Spectroscopy
48
Biopsy
47
Nivolumab
40
Paclitaxel
35
Gemcitabine
30
Radiosurgery
29
Carboplatin
28
Irinotecan
22
Ipilimumab
22
Cyclophosphamide
22
Cisplatin
22
trastuzumab deruxtecan
21
Leucovorin
19
Capecitabine
19
Fluorouracil
18
Cetuximab
18
Bevacizumab
18
130-nm albumin-bound paclitaxel
18
Pemetrexed
17
Fulvestrant
17
Drug Therapy
16
Docetaxel
16
Taxes
15
Oxaliplatin
15
olaparib
14
abemaciclib
14
Radiotherapy
14
palbociclib
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
AZD 6244
×
1 year
×
Clear all
NCT01933932
2025-11-19
SELECT-1
AstraZeneca
Phase 3
Active not recruiting
510 enrolled
16 charts